ArticleAnnals of surgical oncology2026
The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate our Former Strategy?
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical significance of internal mammary chain sentinel lymph nodes (IMCSNs) remains debated, with no consensus on the diagnostic and prognostic value of IMCSN removal. A supporting argument for IMCSN removal is its aid in adjuvant therapy decisions, whereas opposing arguments are that IMCSN removal rarely alters management and may increase complication risk.
methodsPatients with cN0 breast cancer with internal mammary chain (IMC) drainage on preoperative lymphoscintigraphy between 2012 and 2023 were included. The primary outcome was the clinical impact of IMCSN removal on adjuvant treatment strategy. Secondary outcomes were recurrence-free survival and overall survival, comparing patients with and without IMCSN removal.
resultsIn total, 688 patients with cN0 breast cancer were included. In 141 (20.5%) patients, IMCSN removal was performed, resulting in 11 tumor-positive biopsies (7.8%). In 14 patients (9.9%), IMCSN removal alone led to changes in the adjuvant treatment strategy; 10 patients (6.9%) received IMC irradiation solely because of a tumor-positive IMCSN biopsy, three patients (2.1%) were spared IMC irradiation following a tumor-negative IMCSN biopsy, and one patient (0.7%) received systemic treatment based on a tumor-positive IMCSN biopsy. After a median follow-up of 65.3 months, no significant difference in recurrence-free survival (p = 0.566) or overall survival (p = 0.441) was observed between the IMCSN removal and non-removal groups. DISCUSSION: IMCSN removal has limited clinical impact on adjuvant treatment decisions and does not improve recurrence and survival outcomes. Therefore, we recommend that IMCSN removal not be performed in patients with cN0 breast cancer with IMC drainage on preoperative lymphoscintigraphy.
Indexed as
Identifiers
41486232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.